On Wednesday, the FDA approved a drug that can reduce double chins. This miracle worker is called Kybella and its main ingredient is an artificially produced deoxycholic acid, identical to the natural version of the substance, that is found naturally in the body and has the main property of breaking fat cells.
It is precisely what Kybella does in the chin area, thus breaking the cell membrane of fat cells. The FDA clearly states that the drug may only be used for the treatment of adults with moderate-to-severe fat the submental region, defined as the area below the chin.
Unfortunately, the FDA advises that this drug be used in the chin area and nowhere else. “Using Kybella for the treatment of fat outside of the submental area is not approved and is not recommended.”, they said in their release.
The drug is administered by injection in the submental region and patients are allowed to receive up to as many as 50 injections per treatment. The maximum amount of treatments is six and they must be performed at least one month apart.
It is very important that the drug be administered by a medical professional. It is strongly discouraged that Kybella be administered by anybody else, because the patient needs to fully understand the risks involved with the procedure. Moreover, it is recommended that the procedure be performed in a medical facility, so that it may be intervened quickly in case of complications such as allergic reactions to the drug.
As for the side-effects of the Kybella, they range from the most common ones, that include redness of the skin, swelling, bruising, pain and numbness in the treatment area, to considerably more serious ones such as nerve damage, that may cause an uneven smile and even trouble swallowing.
Two clinical trials have been conducted to verify the safety and effectiveness of this drug. 1,022 adults that presented with moderate and severe submental fat participated in these trial. They were secretly assigned either the drug or a placebo for an the maximum of six courses of treatment. And the results asserted the effectiveness of Kybella, with a clear difference between patients who had received the placebo and those who had received the actual drug.
The company that will be distributing Kybella is Kythera Biopharmaceuticals Inc. and they are expecting booming sales for the revolutionary product, of about $500 million annually.
Taking into account that US consumers only spend around $1 billion on small cosmetic procedures such as anti-wrinkle treatments, Kybella has all the chances to be a hit on the market. According to surveys, most people who come to these clinics said that they would like to be treated with Kybella.
Ultimately, it looks like it is much easier today to rectify small imperfections of the face after the FDA approved a drug that can reduce double chins.
Image Source: globenewswire.com